CPI-0610

a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 10/27/2023 - "Moreover, immunodeficient mice were engrafted with SUDHL2 cells and then treated with CPI-0610 for analysis of tumor burden. " 01/01/2020 - "Methods: We retrieved and reviewed published reports on the clinical trials of twelve BET inhibitors including AZD5153, ABBV-075, BMS-986158, CPI-0610, GSK525762, OTX-015, PLX51107, INCB054329, INCB057643, FT-1101, CC-90010, and ODM-207 for patients with hematological malignancies and solid tumors and summarized their published target genes. "
2.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2020 - "Methods: We retrieved and reviewed published reports on the clinical trials of twelve BET inhibitors including AZD5153, ABBV-075, BMS-986158, CPI-0610, GSK525762, OTX-015, PLX51107, INCB054329, INCB057643, FT-1101, CC-90010, and ODM-207 for patients with hematological malignancies and solid tumors and summarized their published target genes. "
3.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/27/2023 - "A Combination of CPI-0610 and SAHA Induces Apoptosis through STAT3 and p38 Signalling Pathways in Diffuse Large B-cell Lymphoma Cells."
4.	Multiple Myeloma 01/01/2017 - "Here we examined the therapeutic potential of CPI-0610, a potent BET inhibitor currently undergoing phase I clinical testing, in multiple myeloma (MM). " 01/01/2017 - "Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma."

1.	Therapeutics